Entero Therapeutics (ENTO) Projected to Post Quarterly Earnings on Friday

Entero Therapeutics (NASDAQ:ENTO) is anticipated to post its quarterly earnings results before the market opens on Friday, April 4th. Analysts expect Entero Therapeutics to post earnings of ($0.41) per share for the quarter.

Entero Therapeutics Stock Performance

Entero Therapeutics stock opened at $0.41 on Thursday. Entero Therapeutics has a 52-week low of $0.19 and a 52-week high of $3.16. The business has a 50-day simple moving average of $0.51 and a two-hundred day simple moving average of $0.53.

Entero Therapeutics Company Profile

Entero Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of targeted and orally delivered therapies for the treatment of patients with gastrointestinal diseases. The company's pipeline candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides, currently under Phase 2 studies; and capeserod, a selective 5-HT4 receptor partial agonist under Phase 1 studies for the treatment of gastroparesis.